Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials

  • Authors:
    • Chiara Carlomagno
    • Gennaro Daniele
    • Roberto Bianco
    • Roberta Marciano
    • Vincenzo Damiano
    • Elide Matano
    • Lucia Nappi
    • Stefano Pepe
    • Sabino De Placido
    • Giampaolo Tortora
  • View Affiliations

  • Published online on: February 25, 2011     https://doi.org/10.3892/etm.2011.218
  • Pages: 449-455
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The combination of EGFR inhibitors and anti-angiogenic drugs has a strong pre-clinical rationale, yet its use has produced controversial clinical results. We conducted two sequential phase I trials to evaluate the feasibility and the recommended dose of erlotinib when combined with fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab. A total of 21 metastatic colorectal cancer (mCRC) patients were treated in two sequential phase I trials. In the first trial, 12 patients were treated with escalating doses of erlotinib plus FOLFOX. In the second, 9 patients were treated with escalating doses of erlotinib combined with oxaliplatin, capecitabine and bevacizumab. No MTD was reached in either of the trials. The only dose-limiting toxicities observed were neutropenia and diarrhea. No unexpected toxicities were noted. Hematological toxicity was the most frequently noted adverse event with infusional 5FU therapy, while gastrointestinal toxicity was the most common adverse event. In the second trial most patients withdrew from treatment due to toxicity, and less than half completed the therapeutic program as per protocol, mostly due to toxicity. In conclusion, the present study confirms the disappointing results of the double combination of EGFR inhibitors and anti-angiogenic drugs in mCRC patients.
View Figures
View References

Related Articles

Journal Cover

May-June 2011
Volume 2 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, De Placido S, Tortora G, Tortora G, et al: Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. Exp Ther Med 2: 449-455, 2011.
APA
Carlomagno, C., Daniele, G., Bianco, R., Marciano, R., Damiano, V., Matano, E. ... Tortora, G. (2011). Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. Experimental and Therapeutic Medicine, 2, 449-455. https://doi.org/10.3892/etm.2011.218
MLA
Carlomagno, C., Daniele, G., Bianco, R., Marciano, R., Damiano, V., Matano, E., Nappi, L., Pepe, S., De Placido, S., Tortora, G."Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials". Experimental and Therapeutic Medicine 2.3 (2011): 449-455.
Chicago
Carlomagno, C., Daniele, G., Bianco, R., Marciano, R., Damiano, V., Matano, E., Nappi, L., Pepe, S., De Placido, S., Tortora, G."Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials". Experimental and Therapeutic Medicine 2, no. 3 (2011): 449-455. https://doi.org/10.3892/etm.2011.218